Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
GNVC's Cash to Debt is ranked higher than
99% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. GNVC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GNVC' s 10-Year Cash to Debt Range
Min: 0.83  Med: 17.29 Max: No Debt
Current: No Debt
Equity to Asset 0.85
GNVC's Equity to Asset is ranked higher than
73% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GNVC: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
GNVC' s 10-Year Equity to Asset Range
Min: 0.35  Med: 0.74 Max: 0.89
Current: 0.85
0.35
0.89
Interest Coverage No Debt
GNVC's Interest Coverage is ranked higher than
99% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GNVC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GNVC' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: -18.12
M-Score: -1.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -76.70
GNVC's Operating margin (%) is ranked lower than
51% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. GNVC: -76.70 )
Ranked among companies with meaningful Operating margin (%) only.
GNVC' s 10-Year Operating margin (%) Range
Min: -466.81  Med: -140.33 Max: -14.73
Current: -76.7
-466.81
-14.73
Net-margin (%) -76.00
GNVC's Net-margin (%) is ranked lower than
52% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. GNVC: -76.00 )
Ranked among companies with meaningful Net-margin (%) only.
GNVC' s 10-Year Net-margin (%) Range
Min: -432.31  Med: -132.85 Max: -11.32
Current: -76
-432.31
-11.32
ROE (%) -27.37
GNVC's ROE (%) is ranked higher than
53% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. GNVC: -27.37 )
Ranked among companies with meaningful ROE (%) only.
GNVC' s 10-Year ROE (%) Range
Min: -177.18  Med: -61.95 Max: -25.24
Current: -27.37
-177.18
-25.24
ROA (%) -23.13
GNVC's ROA (%) is ranked higher than
53% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. GNVC: -23.13 )
Ranked among companies with meaningful ROA (%) only.
GNVC' s 10-Year ROA (%) Range
Min: -101.98  Med: -46.97 Max: -18.29
Current: -23.13
-101.98
-18.29
ROC (Joel Greenblatt) (%) -1110.81
GNVC's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. GNVC: -1110.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GNVC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1883.37  Med: -642.28 Max: -192.56
Current: -1110.81
-1883.37
-192.56
Revenue Growth (3Y)(%) -34.80
GNVC's Revenue Growth (3Y)(%) is ranked lower than
76% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. GNVC: -34.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GNVC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -67  Med: -20.40 Max: 5.9
Current: -34.8
-67
5.9
EBITDA Growth (3Y)(%) -35.50
GNVC's EBITDA Growth (3Y)(%) is ranked lower than
84% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. GNVC: -35.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GNVC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -43.5  Med: -19.70 Max: 12.1
Current: -35.5
-43.5
12.1
EPS Growth (3Y)(%) -34.90
GNVC's EPS Growth (3Y)(%) is ranked lower than
83% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. GNVC: -34.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GNVC' s 10-Year EPS Growth (3Y)(%) Range
Min: -43.1  Med: -22.40 Max: 9.2
Current: -34.9
-43.1
9.2
» GNVC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

GNVC Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2014

GNVC Guru Trades in Q4 2014

Jim Simons 19,211 sh (New)
» More
Q1 2015

GNVC Guru Trades in Q1 2015

Jim Simons 34,600 sh (+80.11%)
» More
Q2 2015

GNVC Guru Trades in Q2 2015

Jim Simons 50,300 sh (+45.38%)
» More
» Details

Insider Trades

Latest Guru Trades with GNVC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.18
GNVC's P/B is ranked lower than
51% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. GNVC: 4.18 )
Ranked among companies with meaningful P/B only.
GNVC' s 10-Year P/B Range
Min: 0.43  Med: 3.55 Max: 41.53
Current: 4.18
0.43
41.53
P/S 9.67
GNVC's P/S is ranked higher than
52% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. GNVC: 9.67 )
Ranked among companies with meaningful P/S only.
GNVC' s 10-Year P/S Range
Min: 0.63  Med: 4.99 Max: 22.91
Current: 9.67
0.63
22.91
PFCF 84.02
GNVC's PFCF is ranked lower than
72% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. GNVC: 84.02 )
Ranked among companies with meaningful PFCF only.
GNVC' s 10-Year PFCF Range
Min: 28.38  Med: 51.48 Max: 84.34
Current: 84.02
28.38
84.34
Current Ratio 6.59
GNVC's Current Ratio is ranked higher than
63% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. GNVC: 6.59 )
Ranked among companies with meaningful Current Ratio only.
GNVC' s 10-Year Current Ratio Range
Min: 1.46  Med: 4.37 Max: 8.55
Current: 6.59
1.46
8.55
Quick Ratio 6.59
GNVC's Quick Ratio is ranked higher than
64% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. GNVC: 6.59 )
Ranked among companies with meaningful Quick Ratio only.
GNVC' s 10-Year Quick Ratio Range
Min: 1.46  Med: 4.37 Max: 8.55
Current: 6.59
1.46
8.55
Days Sales Outstanding 23.78
GNVC's Days Sales Outstanding is ranked higher than
82% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. GNVC: 23.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNVC' s 10-Year Days Sales Outstanding Range
Min: 5.52  Med: 40.08 Max: 71.17
Current: 23.78
5.52
71.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.75
GNVC's Price/Net Cash is ranked higher than
65% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. GNVC: 4.75 )
Ranked among companies with meaningful Price/Net Cash only.
GNVC' s 10-Year Price/Net Cash Range
Min: 0.9  Med: 6.40 Max: 35
Current: 4.75
0.9
35
Price/Net Current Asset Value 4.34
GNVC's Price/Net Current Asset Value is ranked higher than
66% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. GNVC: 4.34 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GNVC' s 10-Year Price/Net Current Asset Value Range
Min: 0.67  Med: 5.42 Max: 18.46
Current: 4.34
0.67
18.46
Price/Tangible Book 4.20
GNVC's Price/Tangible Book is ranked higher than
57% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. GNVC: 4.20 )
Ranked among companies with meaningful Price/Tangible Book only.
GNVC' s 10-Year Price/Tangible Book Range
Min: 0.59  Med: 3.40 Max: 16.67
Current: 4.2
0.59
16.67
Price/Median PS Value 1.94
GNVC's Price/Median PS Value is ranked lower than
76% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. GNVC: 1.94 )
Ranked among companies with meaningful Price/Median PS Value only.
GNVC' s 10-Year Price/Median PS Value Range
Min: 0.17  Med: 1.06 Max: 4.05
Current: 1.94
0.17
4.05
Earnings Yield (Greenblatt) (%) -9.45
GNVC's Earnings Yield (Greenblatt) (%) is ranked lower than
59% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. GNVC: -9.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNVC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -10.04  Med: 355.30 Max: 16429.1
Current: -9.45
-10.04
16429.1

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 1 3 1
EPS($) -0.39 -0.30 -0.46
EPS without NRI($) -0.39 -0.30 -0.46

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GVC1.Germany,
Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV. The Company is developing vaccines against RSV, the single main viral cause of lower respiratory infections in infants and young children. It is developing vaccines for the prevention and treatment of HSV including HSV type 2 the virus responsible for cases of genital herpes. With its collaborators, the Company is generating vaccine candidates for the prevention of dengue fever. Dengue fever is a viral disease spread by mosquitoes that historically affected 50 million to 100 million people each year. With its collaborators the Company is generating vaccine candidates for the prevention of malaria. With its collaborators, the Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks. FMD is a contagious viral disease affecting cows and other animals with cloven hooves. The Company currently has two suppliers for its clinical manufacturing components, one for human health and one for animal health candidates. Currently it procures raw materials, including specialized components known as resins, for its product purification and testing methods from a limited number of suppliers. The Company faces intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The research, development, testing, manufacture, quality, safety, effectiveness, labeling, packaging, storage, approval, distribution, marketing, advertising, and promotion of any biologic products developed by the Company or its collaborators are subject to regulation by federal, state, local, and foreign governmental authorities.
» More Articles for GNVC

Headlines

Articles On GuruFocus.com
GenVec Inc. Reports Operating Results (10-K) Mar 11 2011 
GenVec Inc. Reports Operating Results (10-Q) May 07 2010 
GenVec Inc. Reports Operating Results (10-Q) Nov 06 2009 
GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants Aug 27 2009 
GenVec Inc. Reports Operating Results (10-Q) Aug 07 2009 
GenVec Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
GENVEC INC Financials Aug 19 2015
10-Q for GenVec, Inc. Aug 10 2015
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 07 2015
GenVec Reports Second Quarter 2015 Financial Results Aug 07 2015
GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted... Jun 03 2015
GenVec To Present At The Jefferies Healthcare Conference May 28 2015
GenVec Highlights Proprietary Gorilla Vectors At ASGCT Presentation May 14 2015
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 08 2015
GenVec Reports First Quarter 2015 Financial Results May 08 2015
GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 23 2015
Michael Richman Appointed To GenVec Board Of Directors Apr 22 2015
GenVec Announces Collaboration with the Laboratory of Malaria Immunology & Vaccinology Apr 21 2015
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 24 2015
GenVec Reports Fourth Quarter And 2014 Year-End Financial Results Mar 24 2015
GenVec and TheraBiologics form Collaboration to Develop Neural Stem Cell Mediated Cancer Therapies Mar 23 2015
GenVec to Release Fourth Quarter and Year-End 2014 Financial Results and Conduct a Conference Call... Mar 17 2015
GenVec To Present At The 27th Annual ROTH Conference Mar 02 2015
GenVec To Present At The 17th Annual BIO CEO & Investor Conference Feb 02 2015
GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... Dec 09 2014
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK